Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients

Inclusion Criteria

• •Male or female patient, aged 12 years or older by the time of study entry
• •Patient visiting a participating center for a routine clinical appointment
• •Patient is willing and able to provide a blood sample for IgE and eosinophil levels determination as part of their routine clinical visit
• •Diagnosis of severe asthma for at least one year as defined by:
• •Treatment with guidelines-suggested medications for Global Initiative for Asthma (3) steps 4-5 asthma
• •Patients or their legal guardian, who voluntarily sign and date the informed consent form prior to study entry.